A
Acrivon Therapeutics, Inc. (ACRV)
NGM – Real Time Price. Currency in USD
1.89
-0.02 (-1.05%)
At close: May 12, 2026, 4:00 PM EDT
1.89
-0.00 (-0.07%)
Pre-market: May 13, 2026, 8:25 AM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
1.89
-0.02 (-1.05%)
At close: May 12, 2026, 4:00 PM EDT
1.89
-0.00 (-0.07%)
Pre-market: May 13, 2026, 8:25 AM EDT
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
| Name | Position |
|---|---|
| Dr. Adam D. Levy M.B.A., Ph.D. | CFO & Principal Financial Officer |
| Dr. Eric J. Devroe Ph.D. | Chief Operating Officer |
| Dr. Erick Gamelin M.D., Ph.D. | Chief Development Officer |
| Dr. Jesper V. Olsen Ph.D. | Academic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory Board |
| Dr. Peter Blume-Jensen M.D., Ph.D. | Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer |
| Mr. Bruce Close | Vice President of Quality & Compliance |
| Mr. Joon Jung Ph.D. | VP & Head of Data Science |
| Ms. Katharine Peterson CPA | Vice President of Finance & Accounting |
| Ms. Kristina Masson M.B.A., Ph.D. | Co-Founder, Executive VP of Business Operations, Site Head, Treasurer & Director |
| Ms. Mary-Alice Miller J.D. | Chief Legal Officer & Corporate Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-04-30 | DEFA14A | acrv-20260428.htm |
| 2026-04-30 | DEF 14A | acrv-20260430.htm |
| 2026-03-19 | S-8 | d390264ds8.htm |
| 2026-03-19 | 10-K | acrv-20251231.htm |
| 2026-03-02 | 8-K | d111455d8k.htm |
| 2026-02-27 | 8-K | d116670d8k.htm |
| 2026-01-08 | 8-K | acrv-20260108.htm |
| 2025-11-13 | 10-Q | acrv-20250930.htm |
| 2025-09-05 | 8-K | acrv-20250905.htm |
| 2025-08-13 | 8-K | acrv-20250813.htm |